E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors
复制标题
DOI：
10.1089/10430340150218369
复制
发表时间：
2001-02-10
影响因子：
4.2
通讯作者：
Jensen, SL
中科院分区：
文献类型：
--
作者：
Habib, NA;Sarraf, CE;Jensen, SL
临床研究使用E1B 55-kDa缺失的重组突变腺病毒dl1520进行，以评估其对不可切除的原发性和继发性肝肿瘤患者的毒性和疗效。一项I期研究表明，dl1520在直接瘤内、动脉内或静脉注射时耐受性良好，剂量为3 × 10(11) PFU。组织超微结构检查显示，在细胞核周围的细胞质中存在腺病毒，并显示病毒感染后细胞死亡的两个不同终点：a期TI研究表明，当将dl1520和5-氟尿嘧啶（5-FU）联合输注到肝动脉中时，耐受性良好。为了获得更好的临床反应，需要进一步改进重组载体的设计。
Clinical studies were performed with a recombinant mutant adenovirus with an E1B 55-kDa deletion, dl1520, to assess its toxicity and efficacy in patients with irresectable primary and secondary liver tumors. A phase I study showed that dl1520 was well tolerated when administered directly intratumorally, intraarterially, or intravenously up to a dose of 3 x 10(11) PFU, Ultrastructural examination of tissue showed the presence of adenovirus in cell cytoplasm around the nucleus and revealed two dissimilar end points of cell death after virus infection: a preapoptotic sequence and necrosis, A phase TI study showed that the combination of dl1520 and 5-fluorouracil (5-FU), when infused into the hepatic artery, was well tolerated. Further improvement in the recombinant vector design will be needed in order to achieve better clinical response.